Josep Tabernero Caturla-rekin lankidetzan egindako argitalpenak (26)

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  2. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

  3. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388

2021

  1. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

    Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608

2020

  1. Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas

    Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909

2019

  1. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

    Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131

  2. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

    Cancer Chemotherapy and Pharmacology

  3. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2018

  1. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

    Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609

  2. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set

    ESMO Open, Vol. 3, Núm. 3

  3. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

    Annals of Oncology, Vol. 29, Núm. 1, pp. 119-126

  4. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

    British Journal of Cancer, Vol. 119, Núm. 10, pp. 1208-1214

2017

  1. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

    European Journal of Cancer, Vol. 78, pp. 61-69

  2. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 227-235

  3. Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

    Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608

  4. Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 9, pp. 1999-2007

  5. Proxies of quality of life in metastatic colorectal cancer: Analyses in the RECOURSE trial

    ESMO Open, Vol. 2, Núm. 5

2016

  1. Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI

    Annals of Oncology, Vol. 27, pp. vi198

  2. Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2082-2089

2015

  1. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508